Microthyriaceae sp., an endophytic fungus

In screening for natural products with antiparasitic activity, an endophytic fungus, strain F2611, isolated from above-ground tissue of the tropical grass Paspalum conjugatum (Poaceae) in Panama, was chosen for bioactive principle elucidation. Cultivation on malt extract agar (MEA) followed by bioassayguided chromatographic fractionation of the extract led to the isolation of the new polyketide integrasone B (1) and two known mycotoxins, sterigmatocystin (2) and secosterigmatocystin (3). Sterigmatocystin (2) was found to be the main antiparasitic compound in the fermentation extract of this fungus, possessing potent and selective antiparasitic activity against Trypanosoma cruzi, the cause of Chagas disease, with an IC50 value of 0 13 lmol l 1. Compounds 2 and 3 showed high cytotoxicity against Vero cells (IC50 of 0 06 and 0 97 lmol l 1, respectively). The new natural product integrasone B (1), which was co-purified from the active fractions, constitutes the second report of a natural product possessing an epoxyquinone with a lactone ring and exhibited no significant biological activity. Strain F2611 represents a previously undescribed taxon within the Microthyriaceae (Dothideomycetes, AscomycotaIn screening for natural products with antiparasitic activity, an endophytic fungus, strain F2611, isolated from above-ground tissue of the tropical grass Paspalum conjugatum (Poaceae) in Panama, was chosen for bioactive principle elucidation. Cultivation on malt extract agar (MEA) followed by bioassayguided chromatographic fractionation of the extract led to the isolation of the new polyketide integrasone B (1) and two known mycotoxins, sterigmatocystin (2) and secosterigmatocystin (3). Sterigmatocystin (2) was found to be the main antiparasitic compound in the fermentation extract of this fungus, possessing potent and selective antiparasitic activity against Trypanosoma cruzi, the cause of Chagas disease, with an IC50 value of 0 13 lmol l 1. Compounds 2 and 3 showed high cytotoxicity against Vero cells (IC50 of 0 06 and 0 97 lmol l 1, respectively). The new natural product integrasone B (1), which was co-purified from the active fractions, constitutes the second report of a natural product possessing an epoxyquinone with a lactone ring and exhibited no significant biological activity. Strain F2611 represents a previously undescribed taxon within the Microthyriaceae (Dothideomycetes, AscomycotaLaboratory of Tropical Bioorganic Chemistry, Faculty of Natural Exact Sciences and Technology, University of Panama, Panama City, Republic of Panama Smithsonian Tropical Research Institute, Balboa, Panama City, Republic of Panama Centro de Biodiversidade, Gen omica Integrativa e Funcional (BioFIG), Universidade de Lisboa, Faculdade de Ci^encias, Edif ıcio ICAT/TecLabs, Campus da FCUL, Campo Grande, Lisboa, Portugal Institute for Advanced Scientific Investigation and High Technology Services, National Secretariat of Science, Technology, and Innovation, City of Knowledge, Panama City, Republic of Panama School of Plant Sciences, The University of Arizona, Tucson, AZ, USA Department of Biology, University of Utah, Salt Lake City, UT, USA Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, US

Ecology- and bioassay-guided drug discovery for treatments of tropical parasitic disease: 5α,8α-epidioxycholest-6-en-3β-ol isolated from the mollusk Dolabrifera dolabrifera shows significant activity against Leishmania donovani

An ecology- and bioassay-guided search employed to discover compounds with activity against tropical parasitic diseases and cancer from the opisthobranch mollusk, Dolabrifera dolabrifera, led to the discovery of antileishmanial properties in the known compound, 5α,8α-epidioxycholest-6-en-3β-ol (1). Compound 1 was identified through nuclear magnetic resonance spectroscopy (1H, 13C) and mass spectrometry. The compound was concentrated in the digestive gland of D. dolabrifera, but was not detected in other body parts, fecal matter or mucus. Compound 1 showed an IC50 of 4.9 µM towards the amastigote form of Leishmania donovani compared with an IC50 of 281 µM towards the control Vero cell line, a 57.3-fold difference, and demonstrated no measurable activity against Plasmodium falciparum, Trypanosoma cruzi, and the breast cancer cell line, MCF-7

Ecology- and bioassay-guided drug discovery for treatments of tropical parasitic disease: 5a,8a-epidioxycholest-6-en-3β-isolated from the mollusk dolabrifera dolabrifera shows significant activity against leishmania donovani

An ecology- and bioassay-guided search employed to discover compounds with activity against tropical parasitic diseases and cancer from the opisthobranch mollusk, Dolabrifera dolabrifera, led to the discovery of antileishmanial properties in the known compound, 5a,8a-epidioxycholest-6- en-3ß-ol (1). Compound 1 was identified through nuclear magnetic resonance spectroscopy (1H, 13C) and mass spectrometry. The compound was concentrated in the digestive gland of D. dolabrifera, but was not detected in other body parts, fecal matter or mucus. Compound 1 showed an IC50 of 4.9 μM towards the amastigote form of Leishmania donovani compared with an IC50 of 281 μM towards the control Vero cell line, a 57.3-fold difference, and demonstrated no measurable activity against Plasmodium falciparum, Trypanosoma cruzi, and the breast cancer cell line, MCF-7